• Diagnostic Lead across Heme drug portfolio. Achieved First-Patient-In for first Janssen tumor agnostic study of BALVERSA in FGFR-positive tumors• Established FGFR test standardization across RT-PCR and Next Generation Sequencing testing modalities to support global FGFR testing• Directed and executed FDA Pre-Market Approval Submission for BALVERSA. Achieved Janssen’s first simultaneous FDA approval of a drug and companion diagnostic for selection of patients with metastatic urothelial cancer for treatment with BALVERSA, a novel FGFR inhibitor• Directed diagnostic bridging studies within clinical trials for transition from Clinical Trial Assays to commercial ready Companion Diagnostics• Accountable for molecular screening with an investigational diagnostic test across global clinical testing sites for clinical trial testing across multiple oncology clinical trials and indications• Developed and executed the companion diagnostic strategy for two key oncology assets, driving multiple companion diagnostic programs in multiple indications, including tumor agnostic studies• Accountable for all diagnostic development activities with external partners; primary interface between In Vitro Diagnostic partner and Janssen Compound Development Team and development of junior diagnostic staff